Далбаванцин – новая возможность в лечении инфекций кожи и мягких тканей, вызванных резистентным Staphylococcus aureus


Е.А. Ушкалова, Э.А. Коровякова

Кафедра общей и клинической фармакологии РУДН, Москва
Начиная с 2000-х гг. инфекции, вызванные MRSA (Methicillin-Resistant Staphylococcus aureus), в связи с широким распространением перестали быть исключительно внутрибольничной проблемой. Разработка новых антибиотиков, активных в отношении MRSA, является крайне актуальной задачей. В мае 2014 г. для лечения инфекций кожи и мягких тканей, вызванных грамположительными микроорганизмами, включая MRSA, в США был разрешен новый антибиотик – далбаванцин, являющийся полусинтетическим липогликопептидом. Несмотря на хорошую переносимость, продемонстрированную в клинических исследованиях, эксперты высказывают опасения в отношении безопасности препарата и предостерегают от его применения по незарегистрированным показаниям, например бактериемии или пневмонии. По-видимому, соотношение польза/риск далбаванцина будет определяться при его применении в широкой медицинской практике.

Литература



  1. Pope S.D., Roecker A.M. Dalbavancin: a novel lipo- glycopeptide antibacterial. Pharmacotherapy. 2006;26;908–18.

  2. Rasigade J.P., Dumitrescu O., Lina G. New epidemiolo- gy of Staphylococcus aureus infections. Clin. Microbiol. Infect. 2014 Jun 14. [Epub ahead of print].

  3. Boucher H.W. Challenges in anti-infective development in the era of bad bugs, no drugs: A regulatory perspec- tive using the example of bloodstream infection as an indication. Clin. Infectious Dis. 2010;50:S4–9.

  4. Appelbaum P.C. MRSA--the tip of the iceberg. Clin. Microbiol. Infect. 2006;12(Suppl 2):3–10.

  5. Szekely E., Lorinczi L., Bilca D., et al. Incidence, anti- biotic resistance and clonal relations of MRSA strains isolated from a Romanian university hospital. Acta Microbiol Immunol Hung 2008;55:1–13.

  6. Cowcroft N., Duckworth G., Griffiths C., et al. Deaths involving MRSA: England and Wales, 1993–2006. Health Stat Q. 2008;37:57–6.

  7. Klevens R.M., Edwards J.R., Tenover F.C., et al. Changes in the epidemiology of methicillinresis- tant Staphylococcus aureus in intensive care units in U.S. hospitals, 1992–2003. Clin. Infect. Dis. 2006;42:389–91.

  8. Köck R., Becker K., Cookson B., et al. Methicillinresistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill. 2010;15(41):19688.

  9. National nosocomial infections surveillance (NNIS) sys- tem report, data summary from January 1992 through June 2004 issued October 2004. Am. J. Infect. Control. 2004;32:470–85. Infect Control Hosp Epidemiol. 2008;29(11):996–1011.

  10. Hidron A.I., Edwards J.R., Patel J., et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual sum- mary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007.

  11. Klevens R.M., Morrison M.A., Nadle J. Invasive methi- cillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298(15):1763–71.

  12. Boucher H.W., Corey G.R. Epidemiology of methicil- lin-resistant Staphylococcus aureus. Clin. Infect. Dis. 2008;46(Suppl 5):S344–49.

  13. Ohlsen К. Novel Antibiotics for the Treatment of Staphylococcus aureus. Expert Rev. Clin. Pharmacol. 2009;2(6):661–72.

  14. Stefani S., Chung D.R., Lindsay J.A., Friedrich A.W., Kearns A.M., et al. Methicillin-resistant Staphylo- coccus aureus (MRSA): Global epidemiology and harmonisation of typing methods. Int. J. Antimicrob Agents. 2012;39:273–82.

  15. Zetola N., Francis J.S., Nuermberger E.L., Bishai W.R. 
Community-acquired methicillin-resistant Staphylococcus aureus: An emerging threat. Lancet Infect. Dis 2005;5:275–86.

  16. Roberts J.C., Krueger R.L., Peak K.K., et al. Community- associated methicillin-resistant Staphylococcus aureus epidemic clone USA300 in isolates from Florida and Washington. J.Clin. Microbiol. 2006;44(1):225–26.

  17. Miller L.G., Perdreau-Remington F., Rieg G., et al. Necrotizing fasciitis caused by community-associated methicillin-resistant: Staphylococcus aureus in Los Angeles. N. Engl. J. Med. 2005;352(14):1445–53.

  18. Dominguez T.J. It’s not a spider bite, it’s community- acquired methicillin-resistant Staphylococcus aureus. J. Am. Board .Family Pract. 2004;17(3):220–26.

  19. Heymann W.R. Community-acquired methicillin-resis- tant Staphylococcus aureus infection. J.the Am. Acad. Dermatol. 2005;53(2):318–19.

  20. Weber J.T. Community-associated methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 2005;41(sup- plement 4):S269–72.

  21. Pantosti A. Methicillin-resistant Staphylococcus aureus associated with animals and its relevance to human health. Front Microbiol. 2012;3:127.

  22. Graveland H., Duim B., van Duijkeren E., Heederik D., Wagenaar J.A. Livestock-associated methicillin-resis- tant Staphylococcus aureus in animals and humans. Int. J. Med. Microbiol. 2011;301:630–34.

  23. Himsworth C.G., Parsons K.L., Jardine C., Patrick D.M. Rats, cities, people, and pathogens: A systematic review and narrative synthesis of literature regarding the epidemiology of rat-associated zoonoses in urban centers. Vector Borne Zoonotic Dis. 2013;13:349–59.

  24. Himsworth C.G., Miller R.R., Montoya V., et al. Carriage of methicillin-resistant Staphylococcus aureus by wild urban Norway rats (Rattus norvegicus). PLoS One. 2014;9(2):e87983.

  25. European Food Safety Authority: Analysis of the base- line survey on the prevalence of methicillin¬resistant Staphylococcus aureus (MRSA) in holding with breed- ing pigs in the EU, 2008, Part A: MRSA prevalence estimates. EFSA Journal. 2009;7:1376.

  26. Spoor L.E., McAdam P.R., Weinert L.A., et al. Livestock origin for a human pandemic clone of community- associated methicillin-resistant Staphylococcus aureus. MBio. 2013;4(4): pii: e00356–13.

  27. Gordon R.J., Lowy F.D. Pathogenesis of methicillin- resistant Staphylococcus aureus infection. Clin. Infect. Dis. 2008;46(Suppl. 5):S350–59.

  28. Cosgrove S.E., Sakoulas G., Perencevich E.N., et al. Comparison of mortality associated with methicillin- resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. 2003;36:53–59.

  29. Shurland S., Zhan M., Bradham D.D., Roghmann M.C. Comparison of mortality risk associated with bacte- remia due to methicillin-resistant and methicillin-sus- ceptible Staphylococcus aureus. Infect. Control Hosp. Epidemiol. 2007;28:273–79.

  30. Cosgrove S.E., Qi Y., Kaye K.S., Harbarth S., et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol. 2005;26:166–74.

  31. Zahar J.R., Clech C., Tafflet M., et al. Is methicil- lin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumo- nia? Clin. Infect. Dis. 2005;41:1224–31.

  32. Engemann J.J., Carmeli Y., Cosgrove S.E., et al. Adverse clinical and economic outcomes attributable to methi- cillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis. 2003;36:592–98.

  33. Wilcox MH. MRSA new treatments on the horizon: cur- rent status. Injury. 2011;42(Suppl 5):S42–4.

  34. Projan S.J. Why is big Pharma getting out of anti- bacterial drug discovery? Curr. Opin. Microbiol. 2003;6:427–30.

  35. Witte W., Cuny C., Klare I., Nubel U., Strommen- ger B., Werner G. Emergence and spread of antibiotic- resistant Gram-positive bacterial pathogens. Int. J. Med. Microbiol. 2008;298:365–77.

  36. Gardete S., Tomasz A. Mechanisms of vancomycin resistance in Staphylococcus aureus. J. Clin. Invest. 2014;124(7):2836–40.

  37. Дехнич А.В. Выявление резистентности к метициллину и другим лактамным антибиотикам методом скрининга: Метод. рекомендации для микробиологов. http://www.antibiotic.ru/rus/all/ metod/meticres.

  38. O’Brien D.J., Gould I.M. Does vancomycin have a future in the treatment of skin infections? Curr. Opin. Infect. Dis. 2014;27(2):146–54.

  39. Dalbavancin: New Option for Skin and Skin Structure Infections. Medscape. May 23, 2014.

  40. Pfizer Inc. Pfizer receives approvable letter from FDA for dalbavancin. December 21, 2007. http:// mediaroom.pfizer.com/portal/site/pfizer/index. jsp?ndmViewId=news_view&newsId=20071221005 672&newsLang=en.

  41. Pfizer Inc. Pfizer will withdraw global marketing applica- tions for dalbavancin to conduct a new trial. September 6, 2008.www.pfizer.be/Media/Press+bulletins/Rese arch+and+development+and+business+developme nt/Withdraw+dalbavancin+market+applications.htm.

  42. Zhanel G.G., Calic D., Schweizer F., et al. New lipo- glycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70:859–86.

  43. Bailey J., Summers K.M. Dalbavancin: a new lipo- glycopeptide antibiotic. Am. J. Health Syst. Pharm. 2008;65:599–610.

  44. Burke S.L., Rose W.E. New pharmacological treat- ments for methicillin-resistant Staphylococcus aureus infections. Expert Opin Pharmacother. 2014;15(4): 483–91.

  45. Buckwalter M., Dowell J.A. Population pharmacokinetic analysis of dalbavancin a novel lipoglycopeptide. J. Clin Pharmacol. 2005;45:1279–87.

  46. Raad, Darouiche R., Vazquez J., et al. Efficacy and safety of weekly dalbavancin therapy for catheter related bloodstream infection caused by gram-positive pathogens. Clin. Infect. Dis. 2005;40:374–80.

  47. Boucher H.W., Wilcox M., Talbot G.H., et al. Once-weekly dalbavancin versus daily conven- tional therapy for skin infection. N. Engl. J. Med. 2014;370(23):2169–79.

  48. US Food and Drug Administration. FDA Briefing Document. Anti-infective Drugs Advisory Committee Meeting. March 31, 2014. http:// www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Anti- InfectiveDrugsAdvisoryCommittee/UCM390792.pdf Accessed May 16, 2014.

  49. Jauregui L.E., Babazadeh S., Seltzer E., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infec- tions. Clin. Infect. Dis. 2005;41(10):1407–15.

  50. Chambers H.F. Pharmacology and the Treatment of Complicated Skin and Skin-Structure Infections. N. Engl. J. Med. 2014;370:2238–39. Dalbavancin, Oritavancin Safe, Effective for Skin Infection. Medscape. Jun 06, 2014.

  51. US Food and Drug Administration. FDA Briefing Document. Anti-infective Drugs Advisory Committee Meeting. March 31, 2014. http:// www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Anti- InfectiveDrugsAdvisoryCommittee/UCM390792.pdf Accessed May 16, 2014

  52. Dalbavancin, Oritavancin Safe, Effective for Skin Infection. Medscape. Jun 06, 2014.

  53. New Antibiotic Tedizolid (Sivextro) Approved by FDA. Medscape. Jun 20, 2014.


Об авторах / Для корреспонденции


Е.А. Ушкалова – д.м.н., проф. кафедры общей и клинической фармакологии РУДН; e-mail: eushk@yandex.ru
Э.А. Коровякова – доцент кафедры общей и клинической фармакологии РУДН


Похожие статьи


Бионика Медиа